Finance

Lists
1EXEL:BIT
Exelixis Inc
€45.90
-10.04%
(-5.12) 1D
Aug 18, 4:34:09 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 1EXEL...
Mkt. cap
14.62B
Avg. vol.
1.00
Volume
0.00
52-wk high
€51.02
52-wk low
€29.27
No. of employees
1K
Mkt. cap
14.62B
Avg. vol.
1.00
Volume
0.00
52-wk high
€51.02
52-wk low
€29.27
No. of employees
1K
News stories
From web sources and news partners
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
597.76M
598.66M
610.81M
628.69M
Cost of goods sold
18.57M
26.48M
19.95M
20.66M
Cost of revenue
18.57M
26.48M
19.95M
20.66M
Research and development expenses
199.16M
213.25M
199.92M
211.99M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
123.66M
123.02M
139.60M
147.63M
Operating expense
322.82M
336.27M
339.52M
359.62M
Total operating expenses
341.40M
362.75M
359.47M
380.28M
Operating income
256.36M
235.91M
251.34M
248.41M
Other non operating income
-49.00K
46.00K
219.00K
54.00K
EBT including unusual items
252.41M
252.69M
267.69M
262.68M
EBT excluding unusual items
272.23M
253.38M
267.69M
262.68M
Income tax expense
58.84M
8.16M
57.22M
50.63M
Effective tax rate
23.31%
3.23%
21.38%
19.27%
Other operating expenses
-
-
-
-
Net income
193.58M
244.53M
210.47M
212.05M
Net profit margin
32.38%
40.85%
34.46%
33.73%
Earnings per share
0.78
0.94
0.87
0.91
Interest and investment income
15.92M
17.43M
16.13M
14.21M
Interest expense
-
-
-
-
Net interest expenses
15.92M
17.43M
16.13M
14.21M
Depreciation and amortization charges
-
-
-
-
EBITDA
263.78M
242.86M
258.29M
255.40M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google apps